La cadena de opciones muestra datos clave de las opciones de acciones de Edesa Biotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Edesa Biotech..

Edesa Biotech (NASDAQ:EDSA) Bolsa, Cadena de Opciones

Edesa Biotech

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AMOD

DGLY

EDSA

El Índice de Precios al Productor en EE. UU. subió un 3,5% en enero, superando las previsiones. ¿Cómo reaccionaron los mercados?

Acciones de EE. UU. reaccionan al alza tras el aumento del PPI: ¿qué esperar ahora?

Edesa Biotech Inc

Fermium Research analyst Frank Mitsch upgrades LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) from Hold to Buy and announces $70 price target.

Upgrades

Price Target

Analyst Ratings

Fermium Research Upgrades LyondellBasell Industries to Buy, Announces $70 Price Target

Oppenheimer analyst Jason Helfstein maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and lowers the price target from $260 to $220.

AMZN

Oppenheimer Maintains Outperform on Amazon.com, Lowers Price Target to $220

WEAV

Weave Integrates With Veradigm To Help Streamline Communication Workflows

DA Davidson analyst Gary Tenner maintains Preferred Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFBC#NASDAQ">PFBC</a>) with a Neutral and lowers the price target from $95 to $90.

PFBC

DA Davidson Maintains Neutral on Preferred Bank, Lowers Price Target to $90

Oppenheimer analyst Rayna Kumar initiates coverage on Corpay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) with a Perform rating.

Initiation

CPAY

Oppenheimer Initiates Coverage On Corpay with Perform Rating

DA Davidson analyst Gary Tenner maintains SouthState (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) with a Buy and lowers the price target from $125 to $115.

DA Davidson Maintains Buy on SouthState, Lowers Price Target to $115

DA Davidson analyst Peter Heckmann maintains SS&amp;C Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) with a Buy and lowers the price target from $100 to $94.

SSNC

DA Davidson Maintains Buy on SS&C Technologies Hldgs, Lowers Price Target to $94

DA Davidson analyst Brent Thielman maintains Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) with a Buy and raises the price target from $440 to $465.

DA Davidson Maintains Buy on Comfort Systems USA, Raises Price Target to $465

Verizon Communications Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) shares are trading marginally higher at $42.17 during Monday&#8217;s session, recovering after Friday&#8217;s drop.
The stock dropped last week in reaction to rival T-Mobile US Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), which fell 11% despite reporting record-breaking <a href="https://www.benzinga.com/news/earnings/25/04/44995935/t-mobile-shares-drop-despite-better-than-expected-q1-report-details">first-quarter results</a>.
What To Know: T-Mobile's surge in postpaid phone additions and a 29% jump in diluted earnings per share intensified investor concerns about competitive dynamics in the wireless industry. 
For Verizon, the nation's largest wireless carrier by revenue, the market's response signals growing anxiety over subscriber retention and service revenue stability.
Although Verizon has steadily focused on expanding its premium 5G network, investing heavily in C-band spectrum deployment and premium service offerings like its myPlan customizable wireless plans, <a href="https://www.benzinga.com/pressreleases/25/04/b44994646/t-mobile-leads-the-industry-once-again-with-continued-durable-customer-growth-including-best-ever-">T-Mobile's momentum raises fears</a> that Verizon's pricing power could erode. 
T-Mobile's aggressive subscriber gains, especially in lucrative urban and suburban markets, put pressure on Verizon's high-margin wireless and broadband segments — key drivers of its earnings.
Investors could be worried that Verizon, traditionally viewed as the &#8220;network quality&#8221; leader, may need to offer steeper promotions or risk further churn, challenging its strategy of protecting margins over chasing volume.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/44978343/comcast-hit-hard-by-subscriber-exodus-nearly-630000-customers-gone-in-q1">Comcast Hit Hard By Subscriber Exodus, Nearly 630,000 Customers Gone In Q1</a>
<h2 class="wp-block-heading">How To Buy VZ Stock</h2>
By now you're likely curious about how to participate in the market for Verizon &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Verizon, which is trading at $42172 as of publishing time, $100 would buy you about 2.37 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, VZ has a 52-week high of $47.36 and a 52-week low of $37.58.

TMUS

What's Going On With Verizon (VZ) Stock During Monday's Session?

CIBC analyst Nik Priebe maintains Brookfield Bus Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBU#NYSE">BBU</a>) with a Outperformer and lowers the price target from $34 to $30.

CIBC Maintains Outperformer on Brookfield Bus Partners, Lowers Price Target to $30

<h3>Gainers</h3>
<ul>
<li>Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) shares increased by 28.5% to $1.35 during Monday's regular session. The market value of their outstanding shares is at $61.1 million. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) stock rose 23.11% to $0.64. The company's market cap stands at $15.6 million. </li>
<li>Sabre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) stock moved upwards by 13.92% to $2.5. The market value of their outstanding shares is at $963.0 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) shares increased by 13.88% to $5.74. The market value of their outstanding shares is at $293.3 million. </li>
<li>Yoshiharu Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) shares rose 13.83% to $12.51. The company's market cap stands at $21.6 million. </li>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares moved upwards by 13.09% to $0.45. The company's market cap stands at $35.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock declined by 15.8% to $2.5 during Monday's regular session. The company's market cap stands at $27.5 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares declined by 15.77% to $0.58. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) shares decreased by 13.72% to $0.66. The market value of their outstanding shares is at $5.2 million. </li>
<li>Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares declined by 13.25% to $17.25. The company's market cap stands at $686.9 million. </li>
<li>Raytech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>) shares declined by 12.07% to $2.26. The market value of their outstanding shares is at $39.8 million. </li>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) stock decreased by 10.28% to $2.27. The company's market cap stands at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

GRPN

JDZG

JZXN

MULN

SABR

XELB

YOSH

12 Consumer Discretionary Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 34.5% to $0.01 during Monday's regular session. </li>
<li>CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) shares moved upwards by 32.81% to $29.71. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) stock rose 32.18% to $13.8. The company's market cap stands at $654.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares moved upwards by 30.56% to $1.2. The company's market cap stands at $11.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 24.21% to $2.36. The company's market cap stands at $22.2 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 24.0% to $1.21. The company's market cap stands at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 26.2% to $0.1 during Monday's regular session. The company's market cap stands at $3.9 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 22.6% to $0.89. The company's market cap stands at $3.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 20.8% to $3.96. The market value of their outstanding shares is at $102.9 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 18.94% to $0.26. The market value of their outstanding shares is at $13.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 18.74% to $0.15. The company's market cap stands at $6.7 million. </li>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock declined by 18.52% to $3.52. The company's market cap stands at $129.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

CGON

GELS

HCTI

IBIO

LGMK

SILO

SNTI

SPRB

TARA

ZYBT

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) stock moved upwards by 29.0% to $0.89 during Monday's regular session. The company's market cap stands at $6.6 million. </li>
<li>Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares rose 24.63% to $1.01. The market value of their outstanding shares is at $982.8 million. </li>
<li>Greenwave Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares rose 16.18% to $0.2. The company's market cap stands at $11.6 million. </li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares rose 15.24% to $1.62. The company's market cap stands at $3.3 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares moved upwards by 10.98% to $1.01. The market value of their outstanding shares is at $17.4 million. </li>
<li>ESGL Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESGL#NASDAQ">ESGL</a>) stock moved upwards by 10.86% to $2.04. The company's market cap stands at $82.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intercont (Cayman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCT#NASDAQ">NCT</a>) stock fell 18.1% to $4.53 during Monday's regular session. The market value of their outstanding shares is at $122.5 million. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares fell 15.38% to $3.26. The company's market cap stands at $7.7 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock declined by 14.83% to $0.17. The company's market cap stands at $3.6 million. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) stock declined by 14.77% to $2.05. The company's market cap stands at $102.5 million. </li>
<li>Phoenix Asia Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHOE#NASDAQ">PHOE</a>) shares declined by 14.25% to $3.13. The market value of their outstanding shares is at $67.6 million. </li>
<li>Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) stock decreased by 11.95% to $4.12. The company's market cap stands at $474.2 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

CRGO

ESGL

GWAV

IPDN

PHOE

PLUG

VLRS

WLGS

ZBAI

12 Industrials Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Pony AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) stock moved upwards by 58.1% to $11.09 during Monday's regular session. The company's market cap stands at $3.8 billion. </li>
<li>Aeluma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMU#NASDAQ">ALMU</a>) stock moved upwards by 29.37% to $10.79. The company's market cap stands at $132.2 million. </li>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares rose 25.84% to $4.12. The company's market cap stands at $640.1 million. </li>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) stock rose 17.67% to $4.66. The company's market cap stands at $5.9 million. </li>
<li>Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) stock rose 14.34% to $12.63. The market value of their outstanding shares is at $212.0 million. </li>
<li>Digital Ally (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares moved upwards by 14.23% to $0.03. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Creative Global Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) stock decreased by 22.4% to $1.17 during Monday's regular session. The company's market cap stands at $25.1 million. </li>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) shares fell 16.42% to $1.12. The company's market cap stands at $12.8 million. </li>
<li>Fatpipe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATN#NASDAQ">FATN</a>) shares declined by 12.81% to $9.93. The market value of their outstanding shares is at $136.2 million. </li>
<li>AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) shares decreased by 12.17% to $6.5. The market value of their outstanding shares is at $79.8 million. </li>
<li>Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) shares declined by 12.16% to $9.79. The company's market cap stands at $648.1 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares decreased by 10.98% to $1.82. The company's market cap stands at $47.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMU

AUID

CGTL

CSIQ

FATN

GREE

LCFY

NEON

PONY

WOLF

12 Information Technology Stocks Moving In Monday's Intraday Session

TD Securities analyst Andrew Charles reiterates Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Buy and maintains $490 price target.

Reiteration

TD Securities Reiterates Buy on Domino's Pizza, Maintains $490 Price Target

Celestica Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) reported better-than-expected first-quarter earnings after the <a href="https://www.benzinga.com/quote/CLS/earnings">closing bell on Thursday</a>.
The company posted revenue of $2.65 billion, versus estimates of $2.61 billion. Adjusted earnings came in at $1.20 per share, versus estimates of $1.15 per share.
"Celestica delivered a strong first quarter in 2025, achieving revenue of $2.65 billion and non-GAAP adjusted EPS of $1.20, both surpassing the high end of our guidance ranges. This strong performance was further highlighted by our highest ever adjusted operating margin of 7.1%," said Rob Mionis, president and CEO of Celestica.
Celestica guided for second-quarter revenue of $2.58 billion to $2.73 billion versus estimates of $2.77 billion. The company expects second-quarter adjusted earnings to be in the range of $1.17 to $1.27 per share versus Benzinga Pro estimates of $1.24 per share.
The company also raised its full-year 2025 outlook. Celestica raised its full-year revenue guidance from $10.7 billion to $10.85 billion, and raised its earnings outlook from $4.75 per share to $5 per share. The guidance is still below analyst estimates of $12.54 billion in revenue and earnings of $5.76 per share.
Celestica shares fell 3.3% to trade at $86.13 on Monday.
These analysts made changes to their price targets on Celestica following earnings announcement.
<ul>
<li>Barclays analyst George Wang maintained Celestica with an Overweight rating and lowered the price target from $157 to $126.</li>
<li>JP Morgan analyst Samik Chatterjee maintained Celestica with an Overweight rating and raised the price target from $105 to $115.</li>
<li>RBC Capital analyst Paul Treiber, meanwhile, reiterated the stock with an Outperform rating and maintained a $120 price target.</li>
</ul>
Considering buying CLS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28130258/image-201-1024x599.png" alt="" class="wp-image-891439" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28130258/image-201-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28130258/image-201-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28130258/image-201-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28130258/image-201.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

These Analysts Revise Their Forecasts On Celestica After Q1 Earnings

Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Acadia Realty Trust to report an earnings per share (EPS) of $0.33.
The announcement from Acadia Realty Trust is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 1.39% increase in the share price on the subsequent day.
Here's a look at Acadia Realty Trust's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.33</td>
<td>0.32</td>
<td>0.31</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.32</td>
<td>0.32</td>
<td>0.31</td>
<td>0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745859755_0.png" alt="eps graph" />
<h3>Performance of Acadia Realty Trust Shares</h3>
Shares of Acadia Realty Trust were trading at $19.6 as of April 25. Over the last 52-week period, shares are up 12.96%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Acadia Realty Trust</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Acadia Realty Trust.
With 2 analyst ratings, Acadia Realty Trust has a consensus rating of Buy. The average one-year price target is $23.0, indicating a potential 17.35% upside.
<h3>Comparing Ratings with Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Curbline Properties, InvenTrust Properties and Getty Realty, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Curbline Properties, with an average 1-year price target of $27.5, suggesting a potential 40.31% upside.</li>
<li>Analysts currently favor an Outperform trajectory for InvenTrust Properties, with an average 1-year price target of $32.0, suggesting a potential 63.27% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Getty Realty, with an average 1-year price target of $32.0, suggesting a potential 63.27% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Curbline Properties, InvenTrust Properties and Getty Realty are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acadia Realty Trust</td>
<td>Buy</td>
<td>9.15%</td>
<td>$64.03M</td>
<td>0.47%</td>
</tr>
<tr>
<td>Curbline Properties</td>
<td>Neutral</td>
<td>37.11%</td>
<td>$26.16M</td>
<td>0.73%</td>
</tr>
<tr>
<td>InvenTrust Properties</td>
<td>Outperform</td>
<td>10.06%</td>
<td>$49.65M</td>
<td>0.56%</td>
</tr>
<tr>
<td>Getty Realty</td>
<td>Neutral</td>
<td>-1.29%</td>
<td>$49.77M</td>
<td>1.54%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Acadia Realty Trust ranks in the middle for Consensus rating among its peers. It is at the bottom for Revenue Growth. It is at the top for Gross Profit. It is in the middle for Return on Equity.
<h3>Discovering Acadia Realty Trust: A Closer Look</h3>
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: Core Portfolio segment consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds primarily retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
<h3>Financial Insights: Acadia Realty Trust</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Acadia Realty Trust's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 9.15%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 10.08%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Acadia Realty Trust's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.47%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Acadia Realty Trust's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.22%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Acadia Realty Trust's debt-to-equity ratio is below the industry average. With a ratio of 0.81, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/AKR/earnings">To track all earnings releases for Acadia Realty Trust visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Acadia Realty Trust's Future Earnings

Franklin Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FELE#NASDAQ">FELE</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Franklin Electric will report an earnings per share (EPS) of $0.81. 
The announcement from Franklin Electric is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.06, leading to a 0.02% increase in the share price on the subsequent day.
Here's a look at Franklin Electric's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.66</td>
<td>1.27</td>
<td>1.32</td>
<td>0.74</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.72</td>
<td>1.17</td>
<td>1.26</td>
<td>0.70</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>0.0%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745859745_0.png" alt="eps graph" />
<h3>Performance of Franklin Electric Shares</h3>
Shares of Franklin Electric were trading at $89.17 as of April 25. Over the last 52-week period, shares are down 8.14%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/FELE/earnings">To track all earnings releases for Franklin Electric visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FELE

Franklin Electric's Earnings Outlook

NMI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMIH#NASDAQ">NMIH</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that NMI Holdings will report an earnings per share (EPS) of $1.15. 
Investors in NMI Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 4.77% drop in the share price on the subsequent day.
Here's a look at NMI Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.12</td>
<td>1.14</td>
<td>1.05</td>
<td>0.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.07</td>
<td>1.15</td>
<td>1.20</td>
<td>1.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-5.0%</td>
<td>0.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745859736_0.png" alt="eps graph" />
<h3>NMI Holdings Share Price Analysis</h3>
Shares of NMI Holdings were trading at $33.4 as of April 25. Over the last 52-week period, shares are up 8.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on NMI Holdings</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on NMI Holdings.
NMI Holdings has received a total of 4 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $41.75, the consensus suggests a potential 25.0% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of and PennyMac Financial Servs, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for PennyMac Financial Servs, with an average 1-year price target of $120.4, suggesting a potential 260.48% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for and PennyMac Financial Servs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walker &amp; Dunlop</td>
<td>Outperform</td>
<td>24.46%</td>
<td>$156.35M</td>
<td>2.45%</td>
</tr>
<tr>
<td>PennyMac Financial Servs</td>
<td>Outperform</td>
<td>53.22%</td>
<td>$281.12M</td>
<td>1.97%</td>
</tr>
</tbody>
</table>

Key Takeaway:
NMI Holdings ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, NMI Holdings is at the bottom compared to its peers.
<h3>About NMI Holdings</h3>
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
<h3>Understanding the Numbers: NMI Holdings's Finances</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: NMI Holdings displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 9.99%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: NMI Holdings's net margin excels beyond industry benchmarks, reaching 51.75%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): NMI Holdings's ROE excels beyond industry benchmarks, reaching 3.91%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): NMI Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 2.58%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: NMI Holdings's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/NMIH/earnings">To track all earnings releases for NMI Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NMIH

NMI Holdings's Earnings Outlook

Vicor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Vicor will report an earnings per share (EPS) of $0.29. 
The announcement from Vicor is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.03 in the last quarter, leading to a 22.77% increase in the share price on the following day.
Here's a look at Vicor's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.14</td>
<td>0.06</td>
<td>0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.23</td>
<td>0.26</td>
<td>-0.03</td>
<td>0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>23.0%</td>
<td>14.000000000000002%</td>
<td>0.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745859725_0.png" alt="eps graph" />
<h3>Vicor Share Price Analysis</h3>
Shares of Vicor were trading at $51.49 as of April 25. Over the last 52-week period, shares are up 54.49%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/VICR/earnings">To track all earnings releases for Vicor visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VICR

Earnings Outlook For Vicor

Biotech

Press Releases

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Edesa Biotech Announces Upcoming Conference Schedule

Financing

Edesa Biotech's Founder Makes Strategic Investment in the Company

Edesa Biotech Reports Fiscal Year 2024 Results

Management

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces Chief Financial Officer Transition

HC Wainwright & Co.

Brookline Capital

Comments

Edesa Biotech

Edesa Biotech (EDSA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL